SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artículo

MOTTET, N. et al. Guía de la EAU sobre el cáncer de próstata: Parte II: tratamiento del cáncer de próstata avanzado, recidivante y resistente a la castración. Actas Urol Esp [online]. 2011, vol.35, n.10, pp.565-579. ISSN 0210-4806.

    1. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmich HP, et al. EAU guidelines on prostate cancer. Eur Urol. 2008; 53:68-80. [ Links ]

    2. Modified from Oxford Centre for Evidence-Based Medicine Levels of Evidence (May 2001). Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, and Martin Dawes since November 1998. CEBM. Disponible en: (consultado en noviembre de 2010). [ Links ]

    3. McLeod DG. Hormonal therapy: historical perspective to future directions. Urology. 2003; 61(2 Suppl 1):3-74. [ Links ]

    4. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, et al. Single-therapy an-drogen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2000; 132:566-77. [ Links ]

    5. Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008; 102:1531-8. [ Links ]

    6. Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, Crawford ED, et al. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol. 2010; 57:836-42. [ Links ]

    7. Kaisary AV, Iversen P, Tyrrell CJ, Carroll K, Morris T. Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer?. Prost Cancer Prost Dis. 2001; 4:196-203. [ Links ]

    8. Tyrrell CJ, Denis L, Newling D, Soloway M, Channer K, Cockshott ID. Casodex1 10-200mg daily, used as monotherapy for patients with advanced prostate cancer: an overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group. Eur Urol. 1998; 33:39-53. [ Links ]

    9. Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T. A randomised comparison of "Casodex1" (bicalutamide) 150mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol. 1998; 33:447-56. [ Links ]

    10. Schmitt B, Wilt TJ, Schellhammer PF, DeMasi V, Sartor O, Crawford ED, et al. Combined androgen blockade with non-steroidal antiandrogens for advanced prostate cancer: a systematic review. Urology. 2001; 57:727-32. [ Links ]

    11. Moul JW. Twenty years of controversy surrounding combined an-drogen blockade for advanced prostate cancer. Cancer. 2009; 115:3376-8. [ Links ]

    12. Cruz Guerra NA. Outcomes from the use of maximal androgen blockade in prostate cancer at health area with reference hospital type 2 (1st part). Quality of life: application of EORTC QLQ-C30 instrument. Arch Esp Urol. 2009; 62:431-57. [ Links ]

    13. Abrahamsson P-A. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2010; 57:49-59. [ Links ]

    14. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, et al, Southwest Oncology Group Trial 9346 (INT-0162). Absolute prostate-specific antigen value alter androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006; 24:3984-90. [ Links ]

    15. Yu EY, Gulati R, Telesca D, Jiang P, Tam S, Russell KJ, et al. Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol. 2010; 28:2668-73. [ Links ]

    16. De Leval J, Boca P, Yousef E, Nicolas H, Jeukenne M, Seidel L, et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer. 2002; 1:163-71. [ Links ]

    17. Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol. 2009; 55:1269-77. [ Links ]

    18. Boccon-Gibod L, Hammerer P, Madersbacher S, Mottet N, Prayer-Galetti T, Tunn U. The role of intermittent androgen deprivation in prostate cancer. BJU Int. 2007; 100:738-43. [ Links ]

    19. Studer UE, Whelan P, Albrecht W, Casselman J, De Reijke T, Hauri D, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol. 2006; 24:1868-76. [ Links ]

    20. Studer UE, Collette L, Whelan P, Albrecht W, Casselman J, De Reijke T, et al, EORTC Genitourinary Group. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol. 2008; 53:941-9. [ Links ]

    21. Schröder FH, Kurth K-H, Fossa SD, Hoekstra W, Karthaus PP, De Prijck L, et al. Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial). Eur Urol. 2009; 55:14-22. [ Links ]

    22. Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2004; 171:1141-7. [ Links ]

    23. Byar DP. Proceedings: the Veterans Administration Co-operative Urological Research Group studies of cancer of the prostate. Cancer. 1973; 32:1126-30. [ Links ]

    24. Jordan WP, Blackard CE, Byar DP. Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. South Med J. 1977; 70:1411-3. [ Links ]

    25. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol. 1997;79:235-6. [ Links ]

    26. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999; 341:1781-8. [ Links ]

    27. Nair B, Wilt T, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev. 2002; CD003506. [ Links ]

    28. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, et al, Eastern Cooperative Oncology Group study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006; 7:472-9. [ Links ]

    29. Wong YN, Freedland S, Egleston B, Hudes G, Schwartz JS, Armstrong K. Role of androgen deprivation therapy for node-positive prostate cancer. J Clin Oncol. 2009; 27:100-5. [ Links ]

    30. Morgan SC, Dearnaley DP. Additional therapy for high-risk prostate cancer treated with surgery: what is the evidence?. Expert Rev Anticancer Ther. 2009; 9:939-51. [ Links ]

    31. Serpa Neto A, Tobias-Machado M, Esteves MA, Senra MD, Wroclawski ML, Fonseca FL, et al. A systematic review and meta-analysis of bone metabolism in prostate adeno-carcinoma. BMC Urol. 2010; 10:9. [ Links ]

    32. Isbarn H, Boccon-Gibod L, Carroll PR, Montorsi F, Schulman C, Smith MR, et al. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol. 2009; 55:62-75. [ Links ]

    33. Schulman CC, Irani J, Morote J, Schalken JA, Montorsi F, Chlosta PL, et al. Testosterone measurement in patients with prostate cancer. Eur Urol. 2010; 58:65-74. [ Links ]

    34. Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Raventós CX, et al. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinising hormone releasing hormone agonist therapy in patients with advanced prostate cancer. Urol Int. 2006; 77:135-8. [ Links ]

    35. Perachino M, Cavalli V, Bravi F. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?. BJU Int. 2010; 105:648-51. [ Links ]

    36. Faris JE, Smith MR. Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Curr Opin Endocrinol Diabetes Obes. 2010; 17:240-6. [ Links ]

    37. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2009; 181:1998-2006. [ Links ]

    38. Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco J, Lilja H, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol. 2006; 24:3973-8. [ Links ]

    39. Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Biol Phys. 2006; 65:965-74. [ Links ]

    40. Slovin SF, Wilton AS, Heller G, Scher HI. Time to detectable metastático disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Clin Cancer Res. 2005; 11:8669-73. [ Links ]

    41. Cher ML, Bianco FJ, Lam JS, Davis LP, Grignon DJ, Sakr WA, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol. 1998; 160:1387-91. [ Links ]

    42. Kane CJ, Amling CL, Johnstone PAS, Pak N, Lance RS, Thrasher JB, et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology. 2003; 61:607-11. [ Links ]

    43. Gómez P, Manoharan M, Kim SS, Soloway MS. Radionuclide bone scintig-raphy in patients with biochemical recurrence after radical pros-tatectomy: when is it indicated?. BJU Int. 2004; 94:299-302. [ Links ]

    44. Cirillo S, Petracchini M, Scotti L, Gallo T, Macera A, Bona MC, et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol. 2009; 19:761-9. [ Links ]

    45. Westphalen AC, Coakley FV, Roach M, McCulloch CE, Kurhanewicz J. Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection. Radiology. 2010; 256:485-92. [ Links ]

    46. Pelosi E, Arena V, Skanjeti A, Pirro V, Douroukas A, Pupi A, et al. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse alter radical treatment for prostate cancer. Radiol Med. 2008; 113:895-904. [ Links ]

    47. Breeuwsma AJ, Pruim J, Van den Bergh AC, Leliveld AM, Nijman RJ, Dierckx RA, et al. Detection of local, regional, and distant recurrence in patients with PSA relapse alter external-beam radiotherapy using (11)C-choline positron emission tomography. Int J Radiat Oncol Biol Phys. 2010; 77:160-4. [ Links ]

    48. Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure alter radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010; 37:301-9. [ Links ]

    49. Schillaci O, Calabria F, Tavolozza M, Cicciò C, Carlani M, Caracciolo CR, et al. 18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer. Nucl Med Commun. 2010; 31:39-45. [ Links ]

    50. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, et al. Predicting outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007; 25:2035-41. [ Links ]

    51. Swanson GP, Hussey MA, Tangen CM, Chin J, Messing E, Canby-Hagino E, et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol. 2007; 25:2225-9. [ Links ]

    52. Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008; 299:2760-9. [ Links ]

    53. Goldner G, Dimopoulos J, Pötter R. Is the Roach formula predictive for biochemical outcome in prostate cancer patients with minimal residual disease undergoing local radiotherapy after radical prostatectomy?. Radiother Oncol. 2010; 94:324-7. [ Links ]

    54. Da Pozzo LF, Cozzarini C, Briganti A, Suardi N, Salonia A, Bertini R, et al. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol. 2009; 55:1003-11. [ Links ]

    55. Grossfeld GD, Li YP, Lubeck DP, Broering JM, Mehta SS, Carroll PR. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor. J Urol. 2002; 168:530-5. [ Links ]

    56. Heidenreich A, Semrau R, Thüer D, Pfister D. Radical salvage prostatectomy: treatment of local recurrence of prostate cancer after radiotherapy. Urologe A. 2008; 47:1441-6. [ Links ]

    57. Stephenson AJ, Scardino PT, Bianco FJ, DiBlasio CJ, Fearn PA, Eastham JA. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J Urol. 2004; 172:2239-43. [ Links ]

    58. Heidenreich A, Ohlmann C, Ozgür E, Engelmann U. Functional and oncological outcome of salvage prostatectomy of locally recurrent prostate cancer following radiation therapy. Urologe A. 2006; 45:474-81. [ Links ]

    59. Heidenreich A, Richter S, Thüer D, Pfister D. Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. Eur Urol. 2010; 57:437-45. [ Links ]

    60. Stephenson AJ, Eastham JA. Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. J Clin Oncol. 2005; 23:8198-203. [ Links ]

    61. Pisters LL, Von Eschenbach AC, Scott SM, Swanson DA, Dinney CP, Pettaway CA, et al. The efficacy and complications of salvage cryotherapy of the prostate. J Urol. 1997; 157:921-5. [ Links ]

    62. Cespedes RD, Pisters LL, Von Eschenbach AC, McGuire EJ. Long-term follow-up of incontinence and obstruction after salvage cryosurgical ablation of the prostate: results in 143 patients. J Urol. 1997; 157:237-40. [ Links ]

    63. Eisenberg ML, Shinohara K. Partial salvage cryoablation of the prostate for recurrent prostate cancer after radiotherapy failure. Urology. 2008; 72:1315-8. [ Links ]

    64. Pisters LL, Rewcastle JC, Donnelly BJ, Lugnani FM, Katz AE, Jones JS. Salvage prostate cryoablation: initial results from the cryo on-line data registry. J Urol. 2008; 180:559-63. [ Links ]

    65. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999; 17:3461-7. [ Links ]

    66. Warmuth M, Johansson T, Mad P. Systematic review of the efficacy and safety of high-intensity focussed ultrasound for the primary and salvage treatment of prostate cancer. Eur Urol. 2010; 58:803-15. [ Links ]

    67. Murat F-J, Poissonnier L, Rabilloud M, Belot A, Bouvier R, Rouviere O, et al. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur Urol. 2009; 55:640-9. [ Links ]

    68. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al, Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26:1148-59. [ Links ]

    69. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010; 375:1437-46. [ Links ]

    70. Danila DC, Morris MJ, De Bono JS, Ryan CJ, Denmeade SR, Smith MR, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010; 28:1496-501. [ Links ]

    71. Manni A, Bartholomew M, Caplan R, Boucher A, Santen R, Lipton A, et al. Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol. 1988; 6:1456-66. [ Links ]

    72. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death. Int J Radiat Oncol Biol Phys. 2009; 75:10-5. [ Links ]

    73. Di Lorenzo G, Buonerba C, Autorino R, De Placido S, Sternberg CN. Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs. 2010; 70:983-1000. [ Links ]

    74. Ryan C, Efstathiou E, Smith M, et al. Phase II multicenter study of chemotherapy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone. J Clin Oncol. 2009; 27:15s. Abstract 5046. [ Links ]

    75. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, et al. Docetaxel and estra-mustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351:1513-20. [ Links ]

    76. Tannock IF, De Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al, TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351:1502-12. [ Links ]

    77. Fitzpatrick JM, Anderson J, Sternberg CN, Fleshner N, Fizazi K, Rébillard X, et al. Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach. Crit Rev Oncol Hematol. 2008; 68 Suppl1:S9-22. [ Links ]

    78. Armstrong AJ, Garrett-Mayer E, De Wit R, Tannock I, Eisenberger M. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 2010; 16:203-11. [ Links ]

    79. Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, et al. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer. 2010; 46:1770-2. [ Links ]

    80. Buonerba C, Palmieri G, Di Lorenzo G. Docetaxel rechallenge in castration-resistant prostate cancer: scientific legitimacy of common clinical practice. Eur Urol. 2010; 58:636-7. [ Links ]

    81. Eymard JC, Oudard S, Gravis G, Ferrero JM, Theodore C, Joly F, et al. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int. 2010; 106:974-8. [ Links ]

    82. Ohlmann CH, Markert E, Gerharz M, Dienes HP, Stöckle M, Engelmann U, et al. Improving the efficacy of targeted trials by multiple-marker analysis in castration-resistant prostate cancer. Urol Oncol. 2009 Nov 24. [ Links ]

    83. Fizazi K, Sternberg CN, Fitzpatrick JM, Watson RW, Tabesh M. Role of targeted therapy in the treatment of advanced prostate cancer. BJU Int. 2010; 105:748-67. [ Links ]

    84. Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol. 2009; 27:5431-8. [ Links ]

    85. Sartor AO, Oudard S, Ozguroglu M, De Bono JS, Hansen S, Machiels JP, et al; para los TROPIC Investigators. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC). 2010 Genitourinary Cancers Symposium. Abstract 9. [ Links ]

    86. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al, IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant préstate cancer. N Engl J Med. 2010; 363:411-22. [ Links ]

    87. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94:1458-68. [ Links ]

    88. Fizazi K, Carducci MA, Smith MR, Damião R, Brown JE, Karsh L, et al. A randomized phase III trial of denusomab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol. 28:343s. Abstract LBA4507. [ Links ]

    89. Kuhn JM, Billebaud T, Navratil H, Moulonguet A, Fiet J, Grise P, et al. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med. 1989; 321:413-8. [ Links ]

    90. Crawford ED, Eisenberger MA, McLeod DG, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989; 321:419-24. [ Links ]